glp-1 for nash Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives Resmetirom and GLP-1 agonists for

#PharmaIndustry #GLP1 #PatentCliff #ObesityTreatment #DiabetesCare #IndianPharma #Biologics This is a sharp analysis of why the GLP-1 race is a 'capability' play rather than just a 'commodity' play, especially given the high barriers in peptide API manufacturing and device calibration

WeightWatchers Launches New Behavior Change Program Designed to Support the Unique Needs of Individuals on GLP-1 Medications First-ever nutrition and activity program to complement a GLP-1 weight loss journey for those who receive medication through the new WeightWatchers Clinic or their medical provider NEW YORK, Dec

By cloaking synthetic cores with membranes derived from various cell types, such as cancer cells, stem cells, platelets, or immune cells, CMCNPs inherit functional membrane proteins that improve circulation time, reduce immunogenicity, and enhance tissue-specific targeting [158]

ISRN Inflamm

These findings suggest that early discontinuation may diminish the cardiovascular benefits of GLP-1 RAs, underscoring the importance of treatment persistence when evaluating real-world outcomes

Evidence from pre/post, quasi-experimental, and some randomized interventions supports the benefits of FIM for food security, nutrition security, diet quality, blood glucose control, hypertension, disease self-management, self-perceived physical and mental health, and health care utilization [222]